NCT05723263

Brief Summary

PIONEER is a three-arm, programmatic cluster randomized controlled trial (RCT) to compare effectiveness of three implementation strategies, followed by a mixed-methods implementation evaluation study

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 27, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 10, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

April 1, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
8 months until next milestone

Results Posted

Study results publicly available

May 16, 2025

Completed
Last Updated

December 3, 2025

Status Verified

March 1, 2025

Enrollment Period

1.3 years

First QC Date

January 27, 2023

Results QC Date

April 1, 2025

Last Update Submit

November 19, 2025

Conditions

Keywords

gonorrheasexually transmitted infection (STI)gonorrhea testing among men who have sex with menchlamydia

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Testing for Gonorrhea and Chlamydia

    Defined as the number of eligible participants who accepted and provided laboratory samples for gonorrhea and chlamydia PCR testing out of the total number of eligible participants recruited across the three study arms.

    During enrollment visit

Secondary Outcomes (8)

  • Donation Amount

    Baseline

  • Number of Participants Who Test Positive for Gonorrhea

    Within 2 weeks of enrollment

  • Number of Participants Who Test Positive for Chlamydia

    Within 2 weeks of recruitment

  • Cost Per Test Per Individual

    Baseline - During enrollment visit

  • Mean Self Reported Gratitude Score

    During enrollment visit

  • +3 more secondary outcomes

Other Outcomes (3)

  • Gonorrhea and Chlamydia Testing Uptake by Clinic Type

    During enrollment visit

  • Gonorrhea and Chlamydia Testing Uptake by Sexual Orientation

    During enrollment visit

  • Gonorrhea and Chlamydia Testing Uptake by Age Group

    During enrollment visit

Study Arms (3)

Standard Pay-it-forward

EXPERIMENTAL

* free gonorrhea/chlamydia testing * minimal engagement

Behavioral: Standard Pay-it-forward

Community engaged Pay-it-forward

EXPERIMENTAL

* Free gonorrhea/chlamydia testing * Stronger engagement

Behavioral: Community Engaged Pay-it-forward

Control arm

OTHER

* Test available for a fee * No engagement

Other: Control arm

Interventions

400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).

Standard Pay-it-forward

400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)

Community engaged Pay-it-forward

400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 U.S. Dollars (USD) per test) and no community engagement component

Control arm

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • at least 18 years old
  • have had sex over the past year
  • have not been tested for gonorrhea and chlamydia in the past year
  • reside in the city in the past three months
  • speak Mandarin Chinese or Cantonese
  • mentally capable of providing informed consent to test for gonorrhea and chlamydia
  • own a mobile phone

You may not qualify if:

  • \< 18 years of age

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dermatology Hospital, Institute for Global Health and Sexually Transmitted Diseases, Southern Medical University, China

Guangzhou, Guangdong, 510095, China

Location

Related Publications (2)

  • Liu Y, Zhou K, Li L, Salma G, Fitzpatrick T, Marley G, Zhu Z, Tang W, Tucker JD. Financing STI testing among men in China: A mixed-methods study of pay-it-forward monetary donations. PLoS One. 2026 Feb 13;21(2):e0342595. doi: 10.1371/journal.pone.0342595. eCollection 2026.

  • Marley G, Tan RKJ, Wu D, Wang T, Sun M, Sheng Q, Holly ME, Hlatshwako TG, Wang C, Tang W, Ramaswamy R, Yang L, Luo D, Sylvia SS, Gray K, Van Duin D, Zheng H, Tucker JD. Pay-it-forward gonorrhea and chlamydia testing among men who have sex with men and male STD patients in China: the PIONEER pragmatic, cluster randomized controlled trial protocol. BMC Public Health. 2023 Jun 20;23(1):1182. doi: 10.1186/s12889-023-16095-8.

MeSH Terms

Conditions

GonorrheaChlamydia InfectionsSexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Neisseriaceae InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsSexually Transmitted Diseases, BacterialCommunicable DiseasesGenital DiseasesUrogenital DiseasesChlamydiaceae InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Joseph Tucker, MD, PhD
Organization
University of North Carolina at Chapel Hill

Study Officials

  • Joseph D Tucker, MD

    University of North Carolina

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: hybrid effectiveness-implementation study design
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 27, 2023

First Posted

February 10, 2023

Study Start

April 1, 2023

Primary Completion

July 15, 2024

Study Completion

September 30, 2024

Last Updated

December 3, 2025

Results First Posted

May 16, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Time Frame
9 to 36 months following publication
Access Criteria
Investigator who proposes to use the data has approval from an IRB, IEC, or REB and an executed data use/sharing agreement with UNC.

Locations